DIGIPHARM: Health Industry For You

About Digipharms
The Digipharms solution aims to accelerate the restructuring of the great need for health care. systems for this value-based approach. The lack of current international clinics leads to significant inefficiencies, waste and at least the best health performanceIn the health sector today, there is a lack of incentives for healthcare providers and services to focus on cooperation

Digipharm Platform
The refund platform uses automated "smart contracting" elements, enabling the application of a real-time model flexible pricing system and access to patients between healthcare providers, healthcare payers and information systems and administrative infrastructure involving organizations will eliminate the need for manual data handling and processing prices.Platform rebates significantly reduce operating costs associated with implementing value-based pricing systems and potentially changing drug prices and delivering health services as we know them today.The terms of the personal contracts received will be encrypted on the Reimburse platform through an accessible and automated user interface.implementation when agreement conditions are met. The replacement will also make the implementation of various conditions in the same deal price as the use of smart technology contracts, thereby providing more active and personal pricing solutions while passing through the single connection infrastructure barrier.The dynamic nature of health care and replacement systems allows manufacturers to manage and monitor their budgets more efficiently than the possibility of current comprehensive contract prices will not lead to the use or further costs incurred if a detailed deal is implemented by the current system.For example, it is possible to receive a 50% return of treatment costs after 6 months of patient survival and 75% of treatment costs ranging from 6 to 9 months and then 100% post-administration care costs, based on frequency of side effects, disease indicators and hospitalization which is slower for treatment, with additional additional management burden

Vision Digipharm
Digipharm's vision is to be "the provision of entrepreneurship-based citizen-based services, the generation of innovation evidence and empathy for patients in healthindustry 'using revolutionary blockchain technology. Digipharm aims to utilize new blockchain technology to overcome obstaclesInnovative patient and price access, reducing the cost of all stakeholders, and reducing the lack of infrastructure to drive value enhancement, encouraging innovation and transition expeditions to private healthcare.No platform is available that can provide scalable functionality and pricing solutions to facilitate financing solutions between producer and payer.As pharmaceutical innovation develops further, it is expected hundreds of new drugs will make it approved for the next 5 years. Specialists estimate that of the 7000 developing medicine there are concerning seventieth United Nations agency tend to be initial within the category.Furthermore, individual drugs are used to investigate different areas of the disease to find patients who will benefit from treatment.In some areas of the disease, some new drugs combine to support the best results for patients in active studies (eg, on cancer). With a large number of innovations willing to provide unparalleled benefits to patients, healthcare and producers must work together to adopt appropriate new pricing solutions.cancer drugs have been studied extensively in recent years and are driving growth in 2009, these pharmaceutical drug pipelines create considerable challenges because they often carry heavy price tags that explain the benefits they receive.

The cost of patented cancer

Drugs in the United States alone have increased 5-10 times from the turn of the century, at an average cost of treatment of $ 100,000 a year in patients who are usually responsible for 20-30% of co-payments (Kantarijan et al 2014). High prices for innovative treatments that may or may not work may lead to rejection of patient treatment or choose a less than optimal maintenance plan due to financial difficulties they may face (Zafar et al 2013).In the United States, United Health's leading agents, Aetna and Anthem are close to achieving their current target of 50% of total annual health care through value-added treatments.

PROBLEM AND SOLUTIONS

Barriers to innovative pricing and 'pay performance'Health systems are often asked to make difficult decisions about whether to replace costly pharmacologic therapies and provide access to patients while considering their limited resources. This innovative pricing approach has the ability to overcome the challenges faced by the health care system when assessing new drug funding, to enable the implementation of a 'flexible' pricing scheme to assess treatment rates in relation to the benefits it provides. Unfortunately, health systems around the world do not have the relevant infrastructure to track and implement innovative pricing models such as value-based pricing agreements, and are therefore reluctant to implement such innovative policies. This leads to new pharmacological therapy rejected by the patients most in need,Limitations of conventional real-world evidenceReal-world evidence (RWE) plays an increasingly influential role in informing decision-making within the healthcare industry and it is vital to provide information on value-based health care. However, RWE output delays, data access charges and data collection methods currently negate the many benefits of using this rich data source. The absence of an nearby and comprehensive RWE now prevents health care stakeholders to assess the real time performance and value that therapy delivers in real life clinical repetition as part of a value-based healthcare delivery system.

SOLUTION

Reimburse

The Reimburse platform utilizes the benefits of automated 'smart contracting' and blockchain technology; facilitate the adoption of a truly dynamic innovative pricing solution between healthcare and producer systems, in a safe and secure manner with minimal administrative burden. The use of the Reimbursement platform will accelerate the integration, coordination and delivery of a patient-centered health care system with a focus on improving patient outcomes while accelerating payer-payer mechanisms between payers and producers using mutually sustainable agreements.

Insights

Platform Insights will extract anonymous patient-level data from Reimburse platforms and health information systems to the world's RWE live database. Insights will provide a symbiotic solution with Reimburse to complement the progressive transformation toward a value-based health delivery system. The development of a 'live' repository will allow knowledge integration back into the delivery system in real time to facilitate decision-making, drug development and health-related research. Patients will be given an incentive to donate their health information to the Insight platform and will gain access to valuable health information that is currently unreachable.

Market potential

The Reimburse platform has enormous potential for absorption, with the possibility of being the ultimate platform for innovative pricing solutions for any approved regulatory therapy. There is currently no comparative platform available that can provide scalable dynamic pricing solutions to facilitate funding solutions between producer and payer.

Information on Digipharm token
Token Name: DPH
Total Supply: 100,000,000
Fixed (ERC-20)
Decimal: 18Pre - Sales: 15,000,000 DPH

Basic Price: 1.00 USD
Pre Sold Length: 4 Weeks
Pre-Sales Discount: 35%
Main Sales: 50.000.000 DPH

Week 1: 25% Frozen 25 million tokens
Week 2: 15% Frozen 15 million tokens
Week 3: 10% Frozen 10 million tokens
Week 4: 1.00 USD

Digipharm (DPH) tokens will be used to pay license fees / access on the Digipharm platform. Access fees will always be determined and set in USD value and the number of tokens required will depend on the type of access (producer, patient, payer or provider) combined with the necessary interaction form. The quantity of tokens required for such interactions may change, relative to the market value of the DPH.